November 10, 2025

SPT Labtech and 10x Genomics Partner to Automate Single Cell Workflows

SPT Labtech and 10x Genomics Partner to Automate Single Cell Workflows

Melbourn, UK, and Pleasanton, California, US, 14 October 2025: SPT Labtech, a pioneer in the design and development of laboratory automation and liquid handling solutions, and 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced a strategic partnership to provide automated workflows for single cell research. The collaboration will allow scientists to scale experiments on 10x’s Chromium Single Cell platform, with planned future expansion to the Visium Spatial platform, by providing plug-and-play protocols on SPT Labtech’s firefly® liquid handling platform.

Through this collaboration, firefly® users will gain access to optimized, ready-to-run methods developed with combined expertise from both companies’ application teams. These protocols are designed to streamline single cell assay workflows, and improve reproducibility, efficiency, and scalability. This partnership builds on 10x’s acquisition of Scale Biosciences, a company already partnered with SPT Labtech. Many firefly® users rely on Scale Biosciences chemistries, and this expanded collaboration with 10x will provide researchers access to the company’s full range of single cell and spatial solutions.

The partnership will be spotlighted at the American Society of Human Genetics (ASHG) conference, where data from customer labs, demonstrating how automated liquid handling streamlines single-cell library prep workflows, will be presented. Development of the methods has been informed by application work conducted in customer labs with the preparation workflow addressing one of the biggest challenges in single-cell transcriptomics: scalability.

Morten Frost, Chief Commercial Officer at SPT Labtech, said: “Single cell experiments are a critical area of focus for our firefly community. Working closely with 10x Genomics has been key to understanding the specific challenges and needs of researchers in this space. By making these optimized methods available in the firefly cloud, we are empowering scientists with easier access to cutting-edge tools for single cell discovery, while reducing barriers to adoption of advanced workflows.”

Brooke Murphy, Vice President, Strategic Marketing at 10x Genomics, added:“10x Genomics is committed to enabling researchers everywhere to uncover new insights into biology through our single cell solutions. This partnership with SPT Labtech will allow more labs to seamlessly automate their workflows, combining the flexibility of firefly automation with the robustness of our GEM-X chemistry, ultimately accelerating breakthroughs in human health.”

SPT Labtech and 10x Genomics will exhibit (booth 2487 and 947, respectively) at ASHG, 14th – 18th October, Boston, MA, where customer data and new workflows developed will be highlighted.

Media Contact: Dr Ben Rutter, Zyme Communicationsben.rutter@zymecommunications.com

Our latest News

discover more
PRAME-specific T-cell therapy in an adolescent with metastatic kidney tumor

PRAME-specific T-cell therapy in an adolescent with metastatic kidney tumor

Researchers and physicians at the Hopp Children’s Cancer Center Heidelberg (KiTZ) and other leading cancer centers report an exceptional treatment success in an adolescent with an advanced, therapy-resistant kidney tumor. Using a novel, personalized T-cell therapy, they succeeded in completely pushing back the tumor disease despite multiple metastases. The individual compassionate-use treatment has now been […]

Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026

Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026

COPENHAGEN, Denmark, Aug. 06, 2026 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report second quarter 2026 financial results and provide a business update on Thursday, August 13, 2026, before the open of the U.S. financial markets. Ascendis Pharma also plans to host a conference call and live webcast on August 13, 2026, at 8:00 a.m. Eastern Time (ET) to discuss […]

Can Protein Building Blocks Protect Against Vascular and Kidney Damage?

Can Protein Building Blocks Protect Against Vascular and Kidney Damage?

Researchers from the Medical Faculty Heidelberg, the Medical Faculty Mannheim, and the Centre for Organismal Studies (COS) at Heidelberg University have launched a new research project investigating so-called dipeptides. Some of these naturally occurring protein building blocks are able to neutralize toxic metabolic by-products and may therefore help protect against vascular and kidney damage, particularly […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp